. The leukemic cells may spontaneously induce a tumor specific T cell response in patients 3 .
Circulating mature T cells utilize the / heterodimeric T cell receptor (TCR) for specific recognition of antigenic peptides in context with major histocompatibility complex (MHC) molecules 4, 5 . Genes encoding for the variable domains of the and Clonally expanded T cells with a restricted TCR-BV gene usage have been shown to recognize tumor cells in patients with malignant diseases [8] [9] [10] [11] [12] . Clonal T cell expansions determined as a preferential usage of a restricted TCR-BV gene have also been reported in CLL 13, 14 . However, the functional significance and specificity of such TCR-BV expansions are not clear.
Exploring the specificity and function of T cells in B-CLL may be of importance to better understand immune regulation of the leukemic clone and form a basis for the development of immunotherapeutic strategies. In the present study, TCR-BV gene usage of CD4 and CD8 T cells activated in vitro with autologous leukemic B-CLL cells were analyzed and compared to that of native T cells, using RT-PCR and the CDR3 only.
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MATERIALS AND METHODS

Patients and controls
Three untreated CLL patients (all females) with a mean age of 58 years (range: yr.) were included in the study. The patients have previously been shown to have a specific T cell response against the leukemic B cells 3 . The diagnostic criteria were described earlier 15 . The staging system according to Rai was applied 16 . Clinical characteristics are shown in Table 1 .
Nine healthy age-matched controls with an average age of 60 years (range 54 -67 years) were also included. The study was approved by the Ethical Committee, Karolinska Institute, and informed consent obtained from the blood donors. . CD4 and CD8 T cells were positively selected using anti-CD4 and anti- 
Purification of blood CD4
Activation of T lymphocytes by leukemic B cells
Leukemic B cells were activated as described earlier 3 . Briefly, 20 x 10 6 leukemic B cells in 20 ml were cultured with 2 x 10 6 irradiated (10 000 rads) mitomycin C (SigmaAldrich Sweden AB, Tyresö, Sweden) treated CDw32 cells, anti-CD40 MAb (G28-5 hybridoma producer cell line, American Tissue Culture Collection, USA) (0.1 µg/ml) and human recombinant (r)IL-4 (10 iu/ml) (Schering-Plough Research Institute, Kenilworth, NJ, USA) in 260 ml cell culture flasks. Cells were cultured for 5 days at 37°
C in humified air with 5% CO 2 in RPMI 1640 medium (Gibco, BRL, UK) with 10% heatinactivated pooled human AB serum 1 mM L-glutamin, 100 IU/ml penicillin and 100 µg/ml streptomycin and extensively washed, irradiated (5 000 rads) and used as 
RNA extraction and cDNA synthesis
Total RNA was extracted from 1-2x10 6 CD4 + or CD8 + T cells, using RNAzol B (ams, Biotechnology Europe, Stockholm, Sweden) based on the guanidine thiocyanate phenol-chloroform extraction method as described 14, 19 . First strand cDNA synthesis was performed as described earlier 14 .
only.
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Normalization of TCR B chain specific cDNA concentration
The TCR B chain specific cDNA concentration was normalized using a TCR B chain constant region (BC) specific polymerase chain reaction (PCR) by amplifying part of the TCR BC gene 20 . Briefly, a 5' sense (5' BC) and a 3' anti-sense (3' BC) primer respectively 14 , specific both for the TCR BC1 and TCR BC2 genes, were used in a 30 cycle PCR with serial two fold dilutions of cDNA. The PCR products were then electrophoresed as described earlier 14 . Based on scanned data, equal amounts of TCR B chain specific cDNA were used in the subsequent TCR-BV PCR amplifications.
Analysis of TCR-BV gene usage
PCR amplifications of BV specific cDNA were performed using a panel of 22 TCR-BV specific 5' primers and a TCR BC specific 3' primer as described earlier 14 . To ensure the expected size of the amplified BV-BC PCR products, 8 µl of each product was electrophoresed on 1.5% ethidium bromide stained agarose gels and photographed.
Southern blot analysis of TCRBV-BC PCR products
PCR products were subjected to electrophoresis on agarose gels. The gels were denatured using a solution containing 0.5M NaOH and 1.5M NaCl for 15 min and then neutralized in 0.5M Tris-HCl and 1.5M NaCl for 15 min followed by incubation for 20 min in 10x SSC. The products were transferred to nylon membranes (Amersham Pharmacia Biotech). Membranes were air-dried and baked for 2 hr at 80°C.
5' end-labeling of BC oligonucleotide probe and hybridization to PCR products
A TCR BC specific oligonucleotide probe (BC reporter) 14 14, 22 .
Analysis of CDR3 length polymorphism
CDR3 length polymorphism analysis was performed as described of the total area under the curve area 7, 23 .
Cloning and sequencing
PCR for TCR-BV gene products were performed as described 14 . To avoid mutations during the PCR reaction the Ampli Taq Gold DNA polymerase (PE Biosystems), was used for amplification. Briefly, the PCR product of the corresponding band for a BV family was cut and purified with the QIAquic® gel extraction kit (Qiagen, Helden, Germany). Cloning and sequencing of TCR-BV genes were performed as described only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From earlier 3 . Positive clones were randomly selected for plasmid preparation. The cycle sequencing-PCR was performed using BV specific primers and Bigdye dideoxyterminator (PE Biosystems) in a GeneAmp PCR 2400 system (PE Biosystems) for 25 cycles 24 . Sequencing was carried out using an ABI Prism 310 sequencer (PE Biosystems). Results were analyzed by SeqEd® program (PE Biosystems). CDR3 regions were determined according to Rock et al.
25
. All TCR-BV CDR3 sequences were submitted to NCBI/GeneBank.
Results
TCR-BV gene overexpression in unstimulated native T cells
A value for a given TCR-BV gene expression higher than mean + 3SD of healthy agematched controls is considered an overexpression BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19  BV20   CLL403   Normal   0   5   10   15   20   BV1  BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19 BV1  BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19  BV20   CLL402   Normal   0   5   10   15   20   BV1  BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19 BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19  BV20   CLL411   Normal   0   5   10   15   20   BV1  BV2  BV3  BV4  BV5S-1  BV5S2-3  BV6S1-3  BV7  BV8  BV9  BV10  BV11  BV12  BV13S1  BV13S2  BV14  BV15  BV16  BV17  BV18  BV19 In patient CLL 402,4 TCR-BV-families were expanded, one in the CD4 and 3 in the CD8 subsets (Fig 1A) . The CDR3 pattern was monoclonal in 2 overexpressed CD8 TCR-BV families. An oligoclonal pattern was seen in the overexpressed CD4 TCR-BV population and in another CD8 BV-family. In the non-overexpressed CD4 and CD8 TCR-BV counterparts, all families exhibited a polyclonal pattern (Table 2) . Table 2 . TCR CD R3 l ength poly morphism of native C D4 and CD8 T c ells i n TCR-BV overexpressed and non-overexpressed T c ell subsets In patient CLL 403, 8 expanded TCR-BV families were found (7 in the CD4 subset and 1 in the CD8 fraction) (Fig. 1B) . No monoclonal population was detected among these TCR-BV populations. An oligoclonal expansion was seen within one overexpressed CD4 TCR-BV family and one within a CD8 family. In the remaining six overexpressed CD4 BV families the pattern was polyclonal. In the 7 non-overexpressed CD8 counterparts, four of the TCR-BV families showed an oligoclonal and in three a polyclonal pattern, while in the non-overexpressed CD4 T cell counterparts all patterns were polyclonal.
In patient CLL 411, only one TCR-BV family was overexpressed. This expanded CD4 TCR-BV7 family showed an oligoclonal pattern while in the non-overexpressed CD8 counterpart a monoclonal population was found. Mono/oligoclonal patterns are known to exist in non-overexpressed CD8 TCR-BV families of healthy individuals at a relatively high frequency 27 . In patient CLL 411, 3 randomly selected nonoverexpressed families, were also analyzed. A polyclonal CDR3 pattern was seen in the CD4 as well as in the CD8 subsets.
To summarize, in native blood of CLL patients monoclonal TCR-BV populations were only found within the CD8 population, while oligoclonal subsets were seen both within the CD4 and CD8 T cell fractions. No correlation was found between mono/oligoclonality and TCR-BV expansions.
TCR-BV gene usage of CD4 + and CD8 + T cells stimulated with autologous leukemic B cells
The relative TCR-BV gene usage of CD4 and CD8 T cells after stimulation with the autologous leukemic B cells was compared to that of native T cells ( Figs. 2A-C) . The only.
For (Fig. 2A) . (Figs. 3-5) .
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From In patient CLL403, BV1, BV5S2-3, BV7, BV10, BV11, BV12, BV13S2, BV14, BV15,   BV16, BV17, BV18, BV19, BV20 within the CD4 population and BV5S2-3, BV8, BV9, BV11, BV12, BV13S1, BV13S2, BV17 and BV18 within the CD8 population increased (Fig. 2 B) .
In patient CLL 411, BV2, BV3, BV5S1, BV6S1-3, BV7, BV14 and BV19 in the CD4 fraction increased and BV3, BV6S1-3, BV7, BV9, BV14 and BV17 in the CD8 population (Fig.2C) .
TCR-BV CDR3 length analyses of leukemic cell stimulated T cells
TCR-BV families, which were increased (> 25%) after stimulation within CD4 and/or CD8 T subsets, were further selected for CDR3 length polymorphism analyses. CDR3 length analyses could not be done in all subfamilies due to lack of material (see
Legends to Figs. 2A-C).
In patient CLL 402, the CD4 expanded TCR-BV10 changed from an oligoclonal pattern to a monoclonal pattern in tumor cell stimulated CD4 T cells. Among the analyzed CD8 TCR-BV families (BV2, BV5S1, BV6S1-3, BV10), the size distribution pattern were mono/oligoclonal before stimulation whereas a clear monoclonal pattern emerged in all families after stimulation (Figs. 3A and B) .
In patient CLL 403, the CDR3 length pattern of 6 TCR-BV families were analyzed (Figs. 4A and B) . The polyclonal pattern changed to mono/oligoclonal profiles in both CD4 and CD8 T cells. The BV 5S2-3, BV11, BV13S2, BV17 and BV 18 families within the CD4 T cell fraction changed to a mono/oligoclonal pattern, while BV12 remained polyclonal. In CD8 T cells a monoclonal profile of BV12 and BV13S2 families appeared.
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Fig 3. TCR-BV CDR3 length profile of native CD4 and CD8 T cells and after stimulation with the autologous leukemic B cells in patient CLL402 (see
Fig 4. TCR-BV CDR3 length pattern of native CD4 and CD8 T cells and after stimulation with the autologous leukemic B cells in patient CLL403 (see
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Fig 5. TCR-BV CDR3 length pattern of native CD4 and CD8 T cells and after stimulation with the autologous leukemic B cells in patient CLL411 (see
BV 5S2-3 and BV11 within the CD8 T cell subset remained nearly monoclonal after activation while BV17 and BV18 remained polyclonal.
In patient CLL411, four TCR-BV families were analyzed. After stimulation a more restricted oligoclonal pattern (BV3, BV6 S1-3, BV7, BV14) were noted in all analyzed CD4 T cells, while 3 monoclonal T cell populations (BV6 S1-3, BV7, BV14) appeared within the CD8 T cell fraction. One TCR-BV cell population (BV3) became more oligoclonal (Figs. 5A and B) . 
TCR -BV CDR3 length pattern in non-expanded T cell populations
Mono/oligoclonal patterns of the TCR-BV-CDR3 length distribution profile was not only seen in overexpressed native TCR-BV populations but also in non-overexpressed subsets ( Table 2) . To explore the possibility, that the TCR-BV-CDR3 profile may also change in non-expanded T cell populations after stimulation with autologous leukemic B cells, the CDR3 length polymorphism was analyzed in TCR-BV families with a decreased expression.
These analyses were only done in CD4 and CD8 subpopulations of patient CLL 403, as a representative case of the other patients. All non-expanded TCR-BVs with a relative decrease of 25% were selected (Figs. 6 A-B) . The polyclonal patterns of BV5S1, BV8 and BV9 of the CD4 subset changed to a mono/oligoclonal profile, while BV2, BV3 and BV4 remained polyclonal. BV1, BV15 and BV20 changed from a polyclonal pattern to a mono/oligoclonal pattern in CD8 T cells, while BV4, BV7, BV10 and BV14 remained monoclonal (Figs 6A and B) . Fig. 2B ). 
Fig 6. TCR-BV CDR3 length pattern of native CD4 and CD8 T cells and after stimulation with the autologous leukemic B cells in patient CLL403 (see
Cloning and sequencing
To further analyze and confirm monoclonality, sequences analyses were done of the CDR3 of individual TCR-BV families stimulated with leukemic B cells.
In patient CLL 403, the non-overexpressed native TCR-BV13S2 family within the CD4 subset expanded upon stimulation with leukemic B with a monoclonal CDR3 profile (Figs. 2B, 4A ). BV13S2 -BJ2S5 accounted for about 4% of all JBs before activation with the leukemic cell but after stimulation 100% of all JBs were BV-RRSGSLV-BJ2S5 rearranged (Table 3) . 
cDN A from the populations indicated was PCR-ampli fied with BV-BC primers a nd cloned into vector (see materials a nd methods). The TCR j oining segments ( BJ r egions) w ere eluted by c omparing to the BJ gene segments i n the Gene bank. The NDN-region nucleotides w ere defined as any nucleotide that could not have been acc ounted for by any of the germline of BVs o r BJs s equence. BV is TCR beta variable region s egment gene. only.
For
org From
In patient CLL 402 the BV10 family within the CD8 subset was not over-expressed in native T cells (Fig. 1A) , but a dramatic expansion was noted after stimulation with autologous leukemic B cells (Fig. 2A) . The CDR3 pattern was monoclonal before as well as after leukemic cell activation (Fig. 3B) . Sequencing revealed identical nucleotide sequences of all BJ2S1 before and after activation (Table 4) . 
